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Introduction
Brain Slices: We Have a Problem
In the 1950s Henry McIlwain popularised the use of surgi-
cally isolated brain slices as a means to study in vitro the 
biochemical and electrical activity of the mammalian brain 
[1]. Whilst this was, and remains, an extremely valuable 
model system, it was clear to McIlwain that the brain slice 
was biochemically very different from the intact brain [2–7]. 
This appreciation had come from extensive studies in his 
own lab, but also from others, that had shown very rapid 
post mortem changes in the brains of animals, not least of 
which in ATP and phosphocreatine, which, by donating a 
phosphate to ADP, delays the loss of ATP (Fig. 1) [8, 9]. 
This rapidity of decline of ATP and phosphocreatine was 
understood at the time to reflect the high metabolic rate of 
the brain [2]. We now know that the majority of cerebral 
metabolism is directed primarily towards supporting synap-
tic transmission [10], and which explains the ATP-sparing 
influence of suppressing neuronal activity with anaesthesia 
during cerebral ischemia [11].
Whilst phosphocreatine levels could be returned close to 
values reported in vivo by inclusion of creatine in the incu-
bation medium [4], and which provided reassurance as to the 
biochemical viability of brain slices and the general validity 
of the slice approach, restoring ATP levels provided to be 
more of a challenge. This challenge has persisted, not helped 
by the steep oxygen gradients found in brain slices [12–14] 
that may exacerbate the initial insult, hamper metabolic res-
titution, and indeed confound experimental observations [15, 
16]. Thus, for the most part, ATP in brain slices remains 
at approximately 50% of the levels found in vivo. This has 
led to the uncharitable description of brain slices as “half 
dead”, but there is some (metabolic) truth in Konstantin 
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Hossmann’s assertion that brain slices reflect a brain in a 
post-ischemic, post-traumatic state [17].
ATP: More Than Just Currency
It should go without saying that the ATP content of brain 
slices is important: ATP is the primary energy currency of 
all cells; it powers the  Na+/K+ ATPase that is responsible 
for the maintenance of the resting membrane potential and 
the restoration of ionic homeostasis after action poten-
tials and synaptic activity, and which alone accounts for 
the majority of the brain’s energy budget [10, 18]. ATP 
critically regulates the ability of kinases to phosphorylate 
substrates, and is required for protein synthesis, both of 
which are important for commonly studied slice phenom-
ena such as long-term potentiation (LTP) [19]. ATP also 
has signalling properties in its own right through at least 
seven ionotropic  (P2X1−7) and eight G protein-coupled 
receptors (GPCRs;  P2Y1,2,4,6,11,12,13,14), and indirectly 
through its metabolism to ADP  (P2Y1,12,13 agonist) and 
adenosine, which has pronounced actions on the CNS 
through its four GPCRs  (A1,  A2A,  A2B,  A3) [20]. Moreover, 
the ratio of ATP:AMP critically regulates the activity of 
AMP-activated protein kinase (AMPK), an enzyme that is 
known to regulate a number of ion channels and which is 
increasingly being implicated in a host of CNS functions 
[21, 22]. Importantly for slice physiologists, the activity of 
AMPK is greater in slices incubated at room temperature 
(22 °C) compared to ~34 °C [23]. This increased activ-
ity was associated with a lower ATP:AMP ratio at room 
temperature, likely due to the temperature-dependence 
of adenylate kinase, which interconverts ATP, ADP and 
Fig. 1  Adenine nucleotide metabolism and synthesis via the purine 
salvage pathway. ATP breakdown results in the production of aden-
osine (ADO) and other metabolites that can be lost from the brain 
via equilibrative nucleoside transporters (light grey spheres) into the 
blood. The purine salvage pathway restores adenine nucleotide lev-
els via HPRT (hypoxanthine to IMP) and APRT (adenine to AMP). 
These reactions require PRPP, a product of the pentose phosphate 
pathway from which ribose-5-phosphate emerges. Ribose-5-phos-
phate can be formed directly from d-ribose by ribokinase (10), or 
via isomerisation of inosine (INO)-derived ribose-1-phosphate (14), 
thereby increasing PRPP levels. Adenine and d-ribose feed into the 
salvage pathway and increase tissue ATP levels via adenylate kinase-
mediated phosphorylation of AMP and thence to ATP (3). AMP can 
also be formed from adenosine via adenosine kinase (5). Allopurinol 
(Allo), following its conversion to oxypurinol (8), prevents the break-
down of hypoxanthine (HX) to xanthine (X), and from xanthine to 
uric acid (U). Uric acid has its own bidirectional transporter (dark 
grey sphere). Creatine can buffer the decline in ATP levels via cre-
atine kinase-catalysed substrate-level phosphorylation of ADP (1). 1 
creatine kinase; 2 ATPases; 3 adenylate kinases; 4 5′nucleotidase; 5 
adenosine kinase; 6 adenosine deaminase; 7 purine nucleoside phos-
phorylase; 8 xanthine oxidase; 9 ribulose 5-phosphate isomerase; 10 
ribokinase; 11 phosphoribosylpyrophosphate synthetase; 12 adeny-
losuccinate synthetase; 13 adenylosuccinate lyase; 14 phosphopen-
tomutase; APRT adenine phosphoribosyltransferase; HPRT hypox-
anthine–guanine phosphoribosyltransferase; PRPP phosphoribosyl 
pyrophosphate. Adenine/d-ribose (red), creatine (green) and allopu-
rinol (blue) are colour-coded as they appear in subsequent figures. 
(Color figure online)
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AMP (Fig. 1), and which, like many enzymes, operates 
optimally at physiological temperatures.
Basis for ATP Depletion
Early attempts to restore ATP levels in brain slices were 
made by a colleague of McIlwain’s; brain slices (guinea pig 
cerebral cortex) fixed immediately upon preparation had 
adenine nucleotides at ~55% of the value of brain tissue 
frozen in situ; slices incubated in saline fared worse, with 
adenine nucleotides at ~30% of the in vivo value [24]. This 
value could be improved with the provision of adenine, ino-
sine and, better still, adenosine in the incubation saline, but 
still only to ~34–40% of the in situ value, with additional 
gains (~10%) if a cocktail of adenosine, guanine and creatine 
were included. A similar approach some 40 years later using 
adenine and adenosine yielded comparable observations, but 
with some neuroprotection after oxygen/glucose deprivation 
(OGD) afforded by adenosine [25].
Adenosine, however, is not a practical adjunct to brain 
slice incubation solutions given its profound actions on the 
CNS through its four receptors, some of which provided 
the neuroprotection described above [26, 27]. In the con-
text of brain slice electrophysiology these actions include: 
adenosine-mediated internalisation of the inhibitory adeno-
sine  A1 and  A3 receptors, but not the excitatory  A2A recep-
tor, inhibition of neurotransmitter release, in particular of 
glutamate, and endocytosis of glutamate AMPA receptors 
[28–32]. These effects would dramatically shift the balance 
of excitation and inhibition in the slice preparation and be far 
removed from the in vivo situation where extracellular levels 
of adenosine are kept at a very low levels (typically sub-
micromolar [33]). This low basal tone of adenosine occurs 
primarily via the actions of adenosine kinase, which main-
tains an inward gradient for adenosine through its conversion 
to AMP (Fig. 1); pharmacological or genetic manipulations 
of adenosine kinase have pronounced effects on extracellular 
adenosine and synaptic transmission [34, 35], and its upreg-
ulation in the gliosis associated with brain injury contributes 
to seizure activity and post-traumatic epileptogenesis [36].
Adenine, however, does have potential as an adjunct to 
slice incubation solutions, but not on its own. This appre-
ciation originally stemmed from observations in the heart 
in which periods of anoxia or ischemia were accompanied 
by decreases in myocardial ATP which failed to recover 
upon reperfusion [37]. Various explanations were proposed, 
including dysfunction of mitochondria, and lactic acid and 
pH changes influencing ATP synthesising enzyme kinetics. 
However, one observation suggested that the basis of this 
prolonged post anoxic/ischemic ATP depletion was via the 
loss of ATP precursors from the heart and into the perfu-
sate or blood stream [38] (similar observations were being 
made by Robert Berne around the same time [39]). The 
importance of this loss of precursors, which also occurs in 
man [40], stems from the fact that the heart predominately 
utilises the purine salvage pathway (Fig. 1) for the resyn-
thesis of adenine nucleotides [39]. Thus, the loss of these 
precursors is a plausible explanation for the protracted deple-
tion of cardiac ATP after an ischemic episode.
Myocardium as a Model for ATP Replenishment
Attempts to exploit the purine salvage pathway to restore 
cardiac adenine nucleotides avoided adenosine, since its pro-
found actions on the cardiovascular system had been known 
since the 1920s [41], and inosine, since it too was found 
to exert a direct influence on the heart [42]. Instead, these 
repletion studies, mainly led by the labs of John Foker and 
Heinz-Gerd Zimmer, utilised ribose and adenine infusions 
in various in vitro and in vivo cardiac preparations. These 
studies were successful in restoring both cardiac ATP levels 
and cardiac function after damage caused by ischemia or 
adrenoceptor activation [42–46]. Indeed, such was the inter-
est in this approach that a number of patents were filed in the 
1980s [47]. However, the influence of high doses (50 mg/kg) 
of adenine on the cardiovascular system, its nephrotoxic-
ity when converted to the insoluble 2,8-dihydroxyadenine, 
and the prolonged (24–48 h) intra-cardiac route of infusion 
in some studies has not seen a pursuit of this combined 
approach in humans. Nonetheless, ribose per se is still being 
considered as an adjunct to cardiac rehabilitation [48, 49], 
whilst for adenine, early reports of cardiac benefits of an 
adenine-containing mixture (“Purinor”; [50]) may have led 
to the continued use of Purinor in some countries.
ATP Loss and Replenishment in Brain Tissue: Lessons 
From the Heart
We were initially drawn to the issue of ATP levels in brain 
slices through observations that the release of adenosine 
provoked by hypoxia or OGD, which is largely responsible 
for the inhibition of excitatory synaptic transmission dur-
ing and after metabolic stress in vitro [51–55] and in vivo 
[56–58], was reduced the second time the insult was deliv-
ered (Fig. 2). This manifested as a delay in the depression 
and acceleration in the recovery of excitatory synaptic 
transmission [59]. Whilst this could reflect an artefact of the 
slice preparation, similar observations of reduced adenosine 
release were being made around that time in in vivo prepara-
tions [60–62]. Furthermore, it was known that such repeti-
tive insults to the brain could provoke greater brain damage 
[63], a fact that is of great current concern in the context of 
sport-related concussions [64]. Thus, these observations of 
ATP and adenosine depletion had potential clinical impor-
tance [65].
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One possibility was that the reduced adenosine release 
reflected a depletion of the primary reservoir for adeno-
sine, ATP. This was plausible as the brain, like the heart, 
relies largely upon the purine salvage pathway for the 
restoration of adenine nucleotides, as de novo synthesis 
is slow and not increased after metabolic stress [66–68]. 
Indeed, that the substrates of the purine salvage pathway 
(Fig. 1) are depleted in the ischemic brain are dramatically 
demonstrated by Matrix Assisted Laser Desorption/Ioni-
zation (MALDI) imaging [69] of ex vivo ischemic brain 
tissue. Such studies have revealed the loss of ATP, ADP, 
AMP, adenosine, inosine, hypoxanthine and ribose-5 phos-
phate in the ischemic core, but with accumulations of the 
non-salvageable xanthine and uric acid [70, 71].
Accordingly, the release of adenosine into the perfusate 
could, as in the heart, represent a loss of substrates for the 
purine salvage pathway. That the release of adenosine and 
other purines has been observed in the blood stream in 
humans experiencing cerebral ischemia [72] lends support 
to this possibility, and potentially explains the protracted 
recovery of cerebral bioenergetics after concussion [73]. 
Moreover, purines in the blood could serve as rapid diag-
nostics for stroke.
Attempts to reverse adenosine depletion via the pro-
vision of exogenous adenosine were successful [59], 
suggesting that the slice had the capacity to restore its 
depletable pool of both adenosine and, by inference from 
the work of Thomas [24], ATP. Given the limitations of 
adenosine described above, we subsequently adopted the 
ribose/adenine approach pioneered in the heart.
We initially confirmed observations made on numer-
ous occasions previously eg [74, 75] as to the impov-
erished level of ATP in hippocampal slices, even when 
slices are incubated in supra-physiological levels of glu-
cose (10 mM; Fig. 2) [23]. We additionally examined 
the energy charge (EC) [76] of the slices, which conveys 
the energetic state of a cell and is given by the following 
equation:
such that if all the adenine nucleotides were in the form 
of ATP energy charge would equal 1, whilst if only AMP 
was found the energy charge would equal 0. We found that, 
despite the attenuation in ATP levels, EC was close to values 
recorded in vivo (typically ~0.95) [23, 77]. This suggests 
that a new metabolic equilibrium had been achieved amongst 
the remaining adenine nucleotides. This was only true, 
however, if care was taken to extract adenine nucleotides 
from neutralised fresh tissue; freeze-thawed tissue showed 
EC values similar to those widely reported for brain slices 
(<0.9) [77].
EC =
[ATP] + 0.5[ADP]
[ATP] + [ADP] + [AMP]
Fig. 2  Evidence for adenosine depletion in area CA1 of hippocampal 
slices. Top panel shows adenosine sensor measurements of adeno-
sine (ADO) release in response to two identical periods of oxygen/
glucose deprivation (OGD, 6 min, black bar). Lower panel shows the 
depression and recovery of the simultaneously recorded fEPSP.  Inset 
are fEPSPs taken at the times indicated. Note the reduced release of 
adenosine and reduced effects on the fEPSP during the second period 
(compare fEPSPs c and f taken at comparable times after OGD). Grey 
triangles refer to applications of exogenous adenosine (2 µM) to test 
that the sensor has not run down over this period. In these experi-
ments, differential measurements were made between adenosine and 
inosine biosensors resulting in net adenosine release being detected. 
Adapted from [33]
Fig. 3  Ribose and adenine (RibAde) elevate brain slice adenine 
nucleotides. Incubation in RibAde (+; solid red bar) increased total 
adenine nucleotide content (TAN; Σ(ATP + ADP + AMP)) and ATP 
levels above control levels in hippocampal slices (−; black bar). 
This increase persisted upon washout of RibAde from the incubation 
medium (W; 2 h; checked red bar). When TAN and ATP levels were 
corrected for the dead edges of slices (C; vertical hatched red bar), 
slice TAN and ATP were within the range reported in  vivo (mean, 
dashed line; solid lines ± 1 SD; references found in [23]). **p < 0.01 
sig diff from control slices (−). Adapted from [23]. (Color figure 
online)
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Incubation of hippocampal slices (with overlying neo-
cortex), from the time of cutting, in 10 mM glucose-con-
taining aCSF supplemented with modest concentrations of 
ribose (1 mM) and adenine (50 µM; “RibAde”) resulted in 
increases in the total adenine nucleotide (TAN) and ATP 
content after 2–3 h (Fig. 3; [23]). Neither were effective 
alone, and this seemed to be the optimal concentration of 
both compounds since increases in either did not improve 
ATP levels (or the EC) any further. The increase in cellular 
ATP was stable in that removal of slices from RibAde-con-
taining aCSF to control aCSF still resulted in elevated ATP 
after at least 2 h. Moreover, compensating for the dead cut 
edges of slices (which contribute protein, but no ATP to the 
normalisation to protein content) resulted in estimates of tis-
sue adenine nucleotides that were within the range reported 
in vivo, with estimates of ATP being within a few percent 
of that measured from the rapidly fixed brain (Fig. 3). This 
interesting result, together with the inability of higher con-
centrations of RibAde to enhance ATP levels further, sug-
gests an optimal level of ATP that may be limited by feed-
back inhibition on ATP-synthesising enzymes [67].
The Purine Salvage Pathway as the Vehicle for ATP 
Replenishment
The most likely route by which this ATP is synthesised fol-
lowing the provision of RibAde is via the purine salvage 
pathway, the enzymes of which are found in brain and, 
importantly, are located in the cytosol [67, 78] and provide 
an energetically-efficient means to resynthesise adenine 
nucleotides (Fig. 1). Provision of exogenous ribose and 
its phosphorylation by ribokinase to ribose-5-phosphate 
bypasses the pentose phosphate pathway and is a more direct 
route by which the cellular PRPP pool can be increased. 
Endogenous ribose-1-phosphate derived from inosine can be 
converted to ribose-5-phosphate by phosphopentomutases 
[79] and hence PRPP (Fig. 1) and this has been described 
as the main route by which purines are salvaged [67]. The 
importance of the PRPP pool stems from the fact that it 
contributes the phosphoribose moiety to adenine and hypox-
anthine to generate AMP and IMP via adenine phosphori-
bosyltransferase (APRT) and hypoxanthine-guanine phoso-
phoribosyltransferase (HPRT), respectively. Both enzymes 
are expressed in neurones and astrocytes, with similar levels 
of APRT, but greater expression of HPRT in neurones [80]; 
mutations in HPRT are responsible for Lesch-Nyhan disease 
[81]. Two further steps convert IMP to AMP, which can then 
be converted to ATP via adenylate kinases [68].
Adenylate kinases are interesting enzymes in that there 
are nine isoforms, several of which are found in brain and 
localised to the cytosol [82]. Moreover, most isoforms pos-
sess both nucleoside monophosphate (eg AMP→ADP) and 
nucleoside diphosphate (eg ADP→ATP) kinase activity and 
are capable of utilising phosphate donors other than ATP. 
This diversity of action and promiscuity in the phosphate 
donor ensures that a futile cycle of robbing AT(Peter) to pay 
AD(Paul) does not ensue, but instead the net result is in the 
generation of cytosolic ATP. In highly polarised cells, such 
as neurones, having an extra-mitochondrial source of ATP, 
including via creatine kinase, is very valuable as mitochon-
dria may be remote from the site of neuronal activity. Recent 
detailed serial electron microscopic reconstructions of the 
mature neocortex showed that mitochondria were located 
in only a small fraction of dendritic spines (3 out of 1425 
spines) [83]. This contrasts with the situation in primary 
neuronal cultures where mitochondria or their protrusions 
may enter postsynaptic spines in an activity-dependent man-
ner [84].
The cytosolic location of the enzymes involved in 
purine salvage pathway and the conversion of AMP to ATP 
(Fig. 1) indicates that the local synthesis/replenishment of 
ATP can occur at sites of high activity and independently 
of mitochondria, at least in the short-term, and may per-
mit the “on-demand” nature of synaptic adenosine release 
which dampens presynaptic excitation [85–88]. This local, 
extra-mitochondrial, generation of ATP has an important 
additional advantage in the context of brain injury due 
to the mitochondrial dysfunction that can follow. Such 
injury-induced dysfunction of mitochondria (including that 
incurred after slice preparation [89]) can provoke a host of 
events including mitochondrial consumption of cytosolic 
ATP, and the liberation of reactive oxygen species and pro-
apoptotic factors, all of which would contribute to cellu-
lar damage [90–92]. It should also be remembered that the 
extra-mitochondrial purine salvage pathway and adenosine 
kinase are the mechanisms by which the adenine nucleotide 
backbone is constructed in the form of AMP. Mitochondria 
absolutely rely upon this to import cytosolic ADP and gen-
erate ATP via oxidative phosphorylation or mitochondrial 
adenylate kinases. This may explain the limited success of 
strategies designed to promote ATP synthesis via provision 
of TCA precursors or intermediates such as lactate or pyru-
vate [93], or ketones [94] in the context of acute brain injury. 
These substances do not generally elevate brain slice ATP 
levels, [95–97], and nor indeed does creatine [98], likely 
because the adenine nucleotide backbone is not available.
LTP in ATP‑Replenished Brain Slices: Not What You’d 
Expect
Having now produced slices with physiological levels of 
cellular ATP, an obvious question was to determine the influ-
ence that this would have on long-term potentiation (LTP). 
Our expectation was that creating such “healthy” slices, 
LTP would be enhanced or at least facilitated. In contrast, 
despite there being no effect on basal synaptic transmission 
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or paired-pulse facilitation of RibAde treatment, LTP in 
response to a 1 s tetanus was inhibited (Fig. 4A). We were 
able to establish, using an adenosine  A1 receptor  (A1R) 
antagonist that this was due to greater activity-dependent 
release of adenosine and activation of inhibitory adenosine 
 A1 receptors in RibAde-treated slices (Fig. 4B). To estab-
lish whether this inhibition of LTP was specific to tetanus-
induced LTP, we performed theta-burst stimulation (TBS; 
Fig. 4C–E) LTP using multiples (2, 1, 0.5, respectively) of a 
40 pulse TBS protocol [23]. This induced LTP that was con-
sistently smaller in RibAde-treated slices (Fig. 4F). Indeed, 
LTP was not significantly induced in RibAde-treated slices 
given 20 pulses (0.5 x TBS; Fig. 4E).
We surmised that the greater cellular ATP pool had pro-
vided for a larger releasable pool of adenosine. Measure-
ments using adenosine biosensors confirmed this supposi-
tion (Fig. 5A). That this adenosine was released as such, and 
not as ATP, was suggested by the lack of effect of the ecto-
nucleotidase inhibitor POM-1 [99] on evoked adenosine 
release. That neuronal activity caused by electrical stimula-
tion results in the breakdown of cellular high-energy phos-
phates has been known for quite some time [2], as has the 
fact that this then results in the release of adenosine [100].
An examination of the fEPSP depolarising envelope 
evoked by 100 Hz stimulation revealed a fatigue of the 
fEPSP after approximately 20 pulses, which was exagger-
ated in RibAde-treated slices (Fig. 5B) and which indeed 
was the number of pulses that failed to induce TBS LTP 
in RibAde-treated slices (Fig. 4E). This RibAde-induced 
enhancement of fatigue, as per the inhibition of tetanus-LTP 
(Fig. 4B), reversed upon treatment with the  A1R antagonist 
8-CPT (Fig. 5C). During TBS the depolarising envelope 
in response to 40 pulses (1 x TBS), in contrast to the situ-
ation with the tetanus, showed was no such fatigue of the 
fEPSP, and indeed no obvious effect of RibAde. This implies 
that, in addition to the two properties of TBS that makes 
it effective in inducing LTP, maximising both postsynaptic 
depolarisation (by preventing depolarisation block and 
transmitter depletion) and fatigue of inhibitory GABAergic 
transmission, we may potentially add a third—preventing the 
synaptic accumulation of adenosine during synaptic activity. 
However, since LTP was reduced by RibAde, some inhibi-
tory action of adenosine must occur post-induction, which 
is reminiscent of observations made by Gary Lynch in the 
1990s regarding an early phase of LTP sensitive to adeno-
sine [101]. Direct measurements of adenosine release in 
response to TBS demonstrates the persistence of adenosine 
in the extracellular space after the induction of LTP during 
the early sensitive period (Fig. 5A).
ATP and OGD
Given that our interest in the fate of ATP and adenosine arose 
from work conducted in the context of OGD, we returned to 
this issue to examine the effects of metabolic stress in slices 
preincubated in RibAde. We predicted that the enhanced 
levels of ATP should result in greater adenosine-mediated 
inhibitory actions on excitatory synaptic transmission. As a 
comparator, we performed additional studies using creatine 
(1 mM). By buffering the decline in cellular ATP through 
the creatine kinase-mediated phosphotransfer from phos-
phocreatine to ADP, ATP levels are preserved, and should 
result in a delay and reduction in the appearance of extracel-
lular adenosine, with subsequent reduced inhibitory effects 
on excitatory synaptic transmission. These predictions 
were borne out [98] (Fig. 6) and furthermore demonstrated 
that previous observations [102] concerning the sparing of 
synaptic transmission and neuronal excitability by creatine 
were not entirely due to better ATP-dependent support for 
neurotransmitter release per se, but by reduced extracellu-
lar adenosine release. Similar observations of RibAde and 
creatine facilitating and reducing adenosine release during 
seizure activity, with inhibitory and excitatory actions on 
neuronal activity, respectively, have been made in an in vitro 
model of epileptiform activity [103]. This suggests that the 
seizure-induced depletion of intracellular ATP contributes 
to the rapid accumulation of extracellular adenosine to limit 
the duration, frequency and intensity of seizures [33].
Therapeutic Potential of RibAde‑Based Therapy
Given the ability of RibAde to: elevate ATP levels in the 
injured brain (slice); increase the release of neuroprotec-
tive adenosine in response to physiological and pathologi-
cal stimuli; exert an adenosine  A1R-dependent inhibitory 
influence on excitatory synaptic transmission, and indeed 
to protect cerebellar granule cells when administered after 
OGD [98], to what extent might RibAde-based therapy be 
of value in the injured human brain? This would depend 
upon two key factors, namely (1) the safety and tolerability 
Fig. 4  Elevating cellular ATP with RibAde inhibits LTP via adeno-
sine  A1Rs. A LTP induced by a tetanus (100 Hz/1 s; arrow) resulted 
in robust LTP in standard aCSF, but steadily decremented to base-
line in slices pre-incubated in RibAde. B This decrementing LTP 
was prevented by the adenosine  A1R antagonist 8-CPT (1 µM). Inset 
are fEPSPs taken before (solid lines) and at 60 min after the induc-
tion of LTP (dashed lines) in standard aCSF (control) and RibAde-
treated slices. C–E Decreasing the number of TBS pulses (80, 40, 20, 
respectively) induced LTP, which is consistently lower in RibAde-
treated slices. 20 TBS pulses (0.5 x TBS; E) failed to induce signifi-
cant LTP above baseline. F Summary of LTP at 60 min induced in 
(A) (tetanus; open symbols), C–E Data for 120 pulses from the LTP 
(at 30 min) induced by 3 x TBS used to evoke the adenosine release in 
Fig. 5A. Grey arrowheads indicate where LTP was not significantly 
greater than baseline in RibAde-treated slices. A two-way ANOVA 
(standard aCSF or RibAde treatment vs number of pulses) showed a 
significant effect of treatment on the LTP evoked by the various stim-
ulation protocols  (F1,51 = 6.47688; p = 0.014). Adapted from [23]
◂
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of ribose and adenine, and (2) the extent to which they can 
cross the blood–brain barrier from the systemic circulation.
Safety and Tolerability
On the former, ribose is widely sold as an unregulated nutri-
tional supplement, and large quantities can be ingested orally 
with few side effects [104]. In terms of its intravenous deliv-
ery, escalating doses of ribose were administered intrave-
nously for 12 h in humans until 220 mg/kg was administered 
for 4 h [105]; this dose is higher than that used by Zimmer in 
animal models (200 mg/kg). The study by Gross and Zöllner 
was designed to investigate the mild blood glucose-lowering 
ability of ribose (20–25%), which has been known since the 
1940s. However, in the context of the injured brain, glucose-
lowering therapies may mitigate against the damage caused 
by injury-induced hyperglycaemia [106] and may thus be an 
additional benefit of ribose-based therapy.
Adenine is used to support red blood cell ATP produc-
tion in blood transfusion products. Red blood cells lack both 
mitochondria and de novo synthesis of adenine nucleotides 
and thus rely on the purine salvage pathway. Inclusion of 
adenine in red blood cell transfusion products doubled the 
shelf-life of fresh blood from 3 to 6 weeks, whilst some 
experimental adenine-containing solutions can extend via-
bility to 8–10 weeks [107]. High doses of adenine, however, 
result in toxicity and pathology associated with the xanthine 
oxidase-mediated conversion of adenine to the insoluble 2,8 
dihydroxyadenine, which forms crystals, primarily in the 
kidney. This occurs in APRT deficiency, but can be man-
aged via the use of the xanthine oxidase inhibitor, allopuri-
nol [108]. Given this concern, the introduction of adenine 
as a component of blood transfusion products was delayed 
in some countries until extensive animal and human studies 
established safe limits for intravenous infusion, which are in 
the region of 10–15 mg/kg [109]. However, simulations of 
Fig. 5  Adenosine release during high-frequency stimulation. A 
RibAde increased adenosine release (ADO) in response to TBS 
(arrows). Note the release per individual theta burst (10 trains at 
5 Hz of 4 pulses at 100 Hz) and the sustained post-TBS elevation of 
adenosine, which may be responsible for the subsequent inhibition 
of LTP seen in Fig. 4A. In these experiments the biosensor measures 
the signal recorded from an adenosine sensor, which is sensitive to 
adenosine and its metabolites (inosine, hypoxanthine and xanthine). 
The concentration is thus given as µM′ to indicate that it is not purely 
adenosine that is detected. B The envelope of depolarisation evoked 
by tetanic stimulation fatigues after ~20 pulses, an effect that was 
enhanced by RibAde. This is likely via increased adenosine release 
since (C) this effect was reversed by the  A1R antagonist 8-CPT. In 
contrast, the cumulative depolarisation evoked by TBS (B) was unaf-
fected by RibAde, suggesting that spacing between bursts (200  ms) 
was sufficient to allow lowering of synaptic adenosine to the point 
that it does not interfere with synaptic transmission, at least during 
the period of high-frequency stimulation. Adapted from [23]
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massive blood transfusions at that time indicated that higher 
doses (up to 100 mg/kg) could be tolerated in non-human 
primates [110], and indeed there appears to be only one 
report of adenine-based kidney damage in humans having 
received massive blood transfusions subsequent to major 
trauma or obstetric haemorrhage [111]. Thus, whilst there 
are potential issues associated with adenine, the infusion 
over an extended period, the spontaneous deamination of 
adenine to hypoxanthine, together with the inclusion of 
allopurinol to inhibit its conversion to 2,8 dihydroxyadenine, 
would mitigate against the toxicity of adenine.
In this regard, allopurinol may have benefits additional to 
preventing the conversion of adenine to 2,8 dihydroxyade-
nine; by similarly preventing the conversion of hypoxanthine 
to the non-salvageable xanthine (Fig. 1), allopurinol would 
simultaneously allow greater availability of endogenous 
hypoxanthine for the salvage pathway. Sparing of purines 
during cerebral ischemia by allopurinol or the active metab-
olite oxypurinol has indeed been observed, with functional 
benefits [112, 113]. In addition to purine-sparing actions of 
xanthine oxidase inhibition, such inhibitors would also pre-
vent the production of reactive oxygen species created by the 
subsequent metabolism of xanthine which yields hydrogen 
peroxide. This double benefit of allopurinol is being tested 
in the context of the hypoxic/ischemic neonate to whom 
allopurinol can be administered via the maternal/placental 
circulation [114].
Penetration into the Brain
Since ribose, adenine and indeed allopurinol (eg for the 
treatment of gout) are all in use in man, to what extent might 
they enter the brain via the systemic circulation? Ribose 
is a peculiar compound in that it is extremely permeable 
through lipid membranes, a fact that may have permitted the 
emergence of the ribose-based RNA world [115, 116]. Its 
rapid uptake into brain was demonstrated following track-
ing of radiolabelled ribose [117]. In contrast to the liver 
[117, 118], ribose taken up into the brain is not converted 
to glucose [117]. Whether its uptake occurs by diffusion 
[119, 120] or via a transport mechanism [121] is not clear. 
Uptake may occur via a glucose transporter since it partially 
interferes with glucose transport [122], potentially GLUT2 
[118], which is found in brain [123]. Indeed other members 
of the SLC2 glucose transporter family may, in addition to 
glucose, transport pentose sugars [124, 125].
The evidence for adenine uptake into the brain is clearer 
[126] and likely occurs via the equilibrative nucleoside 
transporters (ENTs; SLC29). ENT1 and ENT2 have a 
fairly ubiquitous cell surface expression and are capable of 
mediating adenine (and hypoxanthine) transport across the 
blood brain barrier [126–129]. It is also likely that allopu-
rinol enters the brain in this way, given its closely related 
structure to hypoxanthine (Fig. 1), and indeed the uptake of 
adenine, hypoxanthine and allopurinol interfere with each 
other [130]. In contrast, access to the brain of creatine is 
severely limited by the absence of creatine transporters on 
the astrocytic endfeet that envelop cerebral blood vessels 
and thereby requiring extensive pre-treatment to demonstrate 
benefits in animal models of brain injury [131].
Therapeutic Potential of RibAde‑Based Therapy: The 
Proof of Concept is in the Stroke Model
These considerations were recently put the test in an in vivo 
model of stroke. Rats underwent a transient, 60 min, fila-
ment occlusion of the middle cerebral artery and, upon 
reperfusion, were administered an intravenous 6 h infusion 
of either saline, RibAde (200 and 10 mg/kg, respectively) 
or RibAde plus an intraperitoneal injection of the xanthine 
oxidase inhibitor, allopurinol, (10 mg/kg; RibAdeAll). MRI 
scans were taken prior to infusion and at day 7. Neurological 
Fig. 6  Modulation of intracellular ATP influences adenosine release 
and synaptic transmission during metabolic stress. Upper panel 
shows adenosine (ADO) release in response to a 5 min period of oxy-
gen/glucose deprivation (OGD, black bar) in control slices, and slices 
pre-incubated in RibAde and creatine. Note greater release of adeno-
sine in RibAde-treated slices and reduced release in slices pre-incu-
bated in creatine (mean of 4 traces for each condition shown). Lower 
traces show fEPSPs, taken at the times indicated and colour-coded as 
per adenosine release, demonstrating the (ii) accelerated depression 
and (iii) delayed recovery of synaptic transmission in RibAde-treated 
slices compared to the delayed depression and accelerated recovery 
in creatine-treated slices. These observations are in keeping with the 
enhanced adenosine release caused by RibAde, and the reduced aden-
osine release caused by creatine. fEPSPs have been normalised to the 
pre-OGD amplitude, which is indicated by the dashed line. Adapted 
from [98]
 Neurochem Res
1 3
testing occurred at days 1, 3 and 7. RibAde- and RibAdeAll-
treated animals displayed a strong tendency towards reduced 
lesion volumes compared to saline-treated rats (Fig. 7), and 
evidence of accelerated neurological recovery (Fig. 8). This 
study [132] was underpowered and did not achieve statisti-
cal significance, but does provide valuable proof of con-
cept information in that these doses of ribose, adenine and 
allopurinol are tolerated, do not cause kidney damage and 
may indeed reduce brain damage and improve functional 
recovery after injury. Subsequent studies would need to be 
adequately powered (we estimate 13 animals per group) and, 
as per all preclinical stroke work, should adhere to appropri-
ate STAIR [133], ARRIVE [134] and the recent IMPROVE 
[135] guidelines.1
Conclusions
The ATP content of brain slices can be restored to val-
ues recorded in vivo. This has immediate consequences 
in increasing the cellular reservoir of the neuromodulator 
adenosine with, as we have shown, quite pronounced effeicts 
on synaptic transmission and plasticity under both physi-
ological and pathological conditions. Wider adoption of Rib-
Ade in slice incubation media might reveal other effects of 
increasing tissue ATP levels, for example in an enhancement 
Fig. 7  RibAde and RibAdeAll (RibAde plus allopurinol) showed a 
trend towards reduced lesion volume in a pre-clinical model of stroke. 
A Individual paired measurements of lesion volume at Day 0 and Day 
7 in the three experimental groups of animals showing a consistent 
trend for substantial lesion shrinkage in the RibAde (n = 8) and Rib-
AdeAll (n = 8) groups compared to saline controls (n = 6). Grey hori-
zontal bars show mean lesion volume by day. B Change in lesion vol-
ume between Days 0 and 7 normalized to lesion size on Day 0. Mean 
lesion size (open circles) decreased by 18% in the saline group, 38% 
in the RibAde group and 50% in the RibAdeAll group. Horizontal 
line, median; box 25–75% range; whiskers, ±1SD; X, min and max 
values. Adapted from [132]
Fig. 8  RibAde and RibAdeAll treatment resulted in a tendency 
towards improved neurological outcome after stroke. All animals 
scored the maximum value of 18 prior to transient middle cerebral 
artery occlusion (tMCAO; dashed line on A). A Median neurologi-
cal scores (from minimum of 3 to maximum of 18; dashed line) per 
group on Day 1, 3 and 7 after induction of stroke (n = 8 in RibAde 
and RibAdeAll groups and n = 6 in saline group). Bars indicate the 
1st and 3rd quartiles for each data point. Median and quartile values 
are rounded to nearest whole number. Data points for each group have 
been offset for clarity. B Mean neurological scores (±SEM) for each 
day normalised to Day 1 revealed a trend to faster recovery despite 
larger initial lesions in the treatment groups, consistent with the 
greater reduction in lesion size (Fig.  7). Data points for each group 
have been offset for clarity. Adapted from [132]
1 STAIR—Stroke Therapy Academic Industry Roundtable; 
ARRIVE—Animal Research: Reporting of In  Vivo Experiments; 
IMPROVE —Ischaemia Models: Procedural Refinements Of in Vivo 
Experiments.
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in the size of synaptic events mediated by the release of 
ATP and activation of ionotropic P2X receptors, of greater 
modulatory actions of GPCR P2Y receptors, and indeed 
on adenosine receptors beyond the inhibitory  A1 receptors 
whose actions we have studied. Cellular biochemistry may 
also be influenced in terms of appropriate utilization of cel-
lular energy sources, the balance between glycolysis and 
oxidative phosphorylation, andthe kinetics and extent of cel-
lular reactions, such as phosphorylation, that require ATP.
In terms of what RibAde-based approaches may mean 
for the injured brain remains to be seen, but the pilot data 
in the preclinical stroke model are encouraging. The loss of 
substrates for the purine salvage pathway after the cerebral 
ischemia and trauma associated with brain slice preparation 
has strong parallels with what happens during these con-
ditions in humans and experimental animals. Accordingly, 
post-injury infusion of RibAde may be of value in restoring 
cerebral ATP levels in tissue peripheral to the injury, but 
vulnerable to expansion of the damaged area. This penum-
bral tissue is potentially salvageable and the focus of exist-
ing therapies such as thrombectomy or thrombolysis for 
ischemic stroke, and the lowering of intracranial pressure 
after traumatic brain injury. Restoring ATP in these regions 
would: (1) facilitate better maintenance of membrane poten-
tial in the face of depolarising waves (spreading depression/
depolarizations, peri-infarct depolarisations) commonly 
associated with brain injury; (2) allow cells to activate 
reparative mechanisms, such as protein synthesis, which is 
inhibited after injury, and (3) promote the release of greater 
amounts of adenosine with its inhibitory, anticonvulsant 
influence on neuronal activity, and its vasodilatory actions 
on the cerebral vasculature. These actions of adenosine may 
mitigate against the seizure activity frequently seen after 
brain injury, and may prevent entry into an epileptogenic 
state, a common sequela of severe brain injury; improved 
blood flow will deliver oxygen and glucose to help protect 
and repair vulnerable brain tissue.
As speed is of the essence in the treatment of brain injury, 
one could imagine civilian or military paramedics being 
equipped with saline packs containing RibAde, with for 
example, allopurinol (RibAdeAll), in order that treatment 
may be initiated at the point of injury. Given the increase 
in both civilian and military head injury victims, who are 
generally in mid-life or younger, and the ageing population, 
with the associated risk of stroke, such an approach may be 
of value in reducing the consequences of the brain injury 
and the individual and familial suffering that it brings, not 
to mention the huge societal costs of brain injury in terms 
of treatment, care and lost earnings.
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